1.	A Dose-Escalating Study of RO5072759 in Patients With CD20+ Malignant Disease (GAUGUIN) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO20999, NCT00517530
2.	GAUSS: A Study of RO5072759 in Patients With Indolent Non-Hodgkin's Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO21003, NCT00576758
3.	A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GAO4768g, GO25677, NCT01414205
4.	A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GAO4779g, GO01298, NCT01300247
5.	A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GP28331, 2012-002038-34, NCT01685892